12:00 AM
 | 
May 06, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Maribavir: Interim Phase II data

ViroPharma disclosed on its 1Q13 earnings call that interim data from 13 patients in a U.S. Phase II trial showed that twice-daily oral maribavir led to undetectable plasma CMV DNA in 92% of patients. One patient was withdrawn from treatment before clearing virus because of progression of underlying post-transplant complications that led...

Read the full 250 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >